急性髓系白血病及骨髓增生异常综合征患者血管内皮生长因子表达的研究

Expression of marrow vascular endothelial grouth factor in acute myeloid leukemia and myelodysplastic syndrome

目的了解血管内皮生长因子(VEGF)在急性髓系白血病(AML)和骨髓增生异常综合征(MDS)中血管新生的作用。方法用ELISA法检测20例AML及24例MDS患者骨髓单个核细胞培养上清VEGF的表达。结果AML患者骨髓细胞VEGF的水平(267.35～412.30ng/L)高于对照组(128.17ng/L),化疗后完全缓解组的VEGF水平明显下降(P<0.05)化疗后未缓解组的VEGF水平与治疗前比较无显著下降(P>0.05)。MDS高危型(RAEB或RAEBt)中VEGF水平与低危型(RA或RAS)及对照组相比均明显升高(P<0.05),其中RAEBt与AML患者相比差异无显著性(P>0.05)。结论AML及高危型MDS患者骨髓中存在血管新生,VEGF在AML及MDS发病中起着重要作用,VEGF的表达与MDS病程进展有关。

Objective to explore the role of angiogenesis in bone marrow in acute myeloid leukemia (AML) and mylodysplastic syndrome (MDS).Methods Bone marrow culture supernatant was assayed for vascular endothelial growth factor (VEGF) by ELISA in 20 newly diagnosed AML and 24 diagnosed MDS patients.Results Culture supernatant of AML showed higher amount of VEGF (267.4-412.30 ng/L) than that of control (128.17 ng/L),the VEGF expressions reduced to normal after AML patient achieved complete remission (P<0.05) While in non-remission patient did not (P>0.05),but the amount of VEGF in high risk MDS group (RAEB,RAEB-t) was significantly higher than that of control and low risk MDS group (RA,RAS) (P<0.05),There was no significant difference in VEGF.expressions between RAEB-t group and AML group(P>0.05).Conclusions There is remarkable angiogenesis in AML and high risk MDS and VEGF takes an important role in angiogensis.VEGF could be used as a advanced factor in MDS.